Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1703-1715

  Xu, Haiyan ^a,b   Kulkarni, Kaustubh H ^a   Singh, Rashim ^a   Yang, Zhen ^a   Wang, Stephen W J ^a   Tam, Vincent H ^a   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Disposition; Efflux; Flavonoids; Intestine; Metabolism; Naringenin; Transporter

Indexed keywords

DIPYRIDAMOLE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; NARINGENIN; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT; BILIARY EXCRETION; CANNULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DUODENUM; GLUCURONIDATION; HYDROPHILICITY; INTESTINE ABSORPTION; INTESTINE PERFUSION; JEJUNUM; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPYRIDAMOLE; FLAVANONES; GLUCURONIDES; INTESTINES; LEUKOTRIENE ANTAGONISTS; LIVER; MALE; MICROSOMES; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHODIESTERASE INHIBITORS; PROPIONATES; QUINOLINES; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 71949113516     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900013d     Document Type: Article

References (44)

1. Rice-Evans, C.; Miller, N. G.; Paganga, G. Structure antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biol. Med. 1996, 20 (7), 933-956. (Pubitemid 26157509)
2. Lee, S. H.; Park, Y. B.; Bae, K. H.; Bok, S. H.; Kwon, Y. K.; Lee, E. S.; Choi, M. S. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: cholesterol acyltransferase in rats. Ann. Nutr. Metab. 1999, 43 (3), 173-180. (Pubitemid 29494862)
3. Santos, K. F.; Oliveira, T. T.; Nagem, T. J.; Pinto, A. S.; Oliveira, M. G. Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations. Pharmacol. Res. 1999, 40 (6), 493-496.
4. Franke, A. A.; Cooney, R. V.; Henning, S. M.; Custer, L. J. Bioavailability and antioxidant effects of orange juice components in humans. J. Agric. Food Chem. 2005, 53 (13), 5170-5178.
5. Kanno, S.; Tomizawa, A.; Hiura, T.; Osanai, Y.; Shouji, A.; Ujibe, M.; Ohtake, T.; Kimura, K.; Ishikawa, M. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol. Pharm. Bull. 2005, 28 (3), 527-530. (Pubitemid 40879982)
6. Williamson-Hughes, P. S.; Flickinger, B. D.; Messina, M. J.; Empie, M. W. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 2006, 13 (5), 831-839.
7. Benavente-Garcia, O.; Castillo, J.; Alcaraz, M.; Vicente, V.; Del Rio, J. A.; Ortuno, A. Beneficial action of Citrus flavonoids on multiple cancer-related biological pathways. Curr. Cancer Drug Targets 2007, 7 (8), 795-809.
8. Kelly, G. E.; Joannou, G. E.; Reeder, A. Y.; Nelson, C.; Waring, M. A. The variable metabolic response to dietary isoflavones in humans. Proc. Soc. Exp. Biol. Med. 1995, 208 (1), 40-43.
9. Setchell, K. D. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr. 1998, 68 (6 Suppl.), 1333S-1346S.
10. Birt, D. F.; Hendrich, S.; Wang, W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 2001, 90 (2-3), 157-177. (Pubitemid 32913477)
11. Setchell, K. D.; Brown, N. M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B. E.; Brashear, W. T.; Kirschner, A. S.; Cassidy, A.; Heubi, J. E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 2001, 131 (4 Suppl.), 1362S-1375S.
12. Busby, M. G.; Jeffcoat, A. R.; Bloedon, L. T.; Koch, M. A.; Black, T.; Dix, K. J.; Heizer, W. D.; Thomas, B. F.; Hill, J. M.; Crowell, J. A.; Zeisel, S. H. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr. 2002, 75 (1), 126-136. (Pubitemid 34013498)
13. Chen, L.; Zhang, H. Y. Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules 2007, 12 (5), 946-957.
14. Hadi, S. M.; Bhat, S. H.; Azmi, A. S.; Hanif, S.; Shamim, U.; Ullah, M. F. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin. Cancer Biol. 2007, 17 (5), 370-376.
15. Kurzer, M. S.; Xu, X. Dietary phytoestrogens. Annu. Rev. Nutr. 1997, 17, 353-381.
16. Yang, C. S.; Landau, J. M.; Huang, M. T.; Newmark, H. L. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 2001, 21, 381-406. (Pubitemid 32695277)
17. Liu, Y.; Hu, M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab. Dispos. 2002, 30 (4), 370-377. (Pubitemid 34263820)
18. Chen, J.; Lin, H.; Hu, M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmacol. Exp. Ther. 2003, 304 (3), 1228-1235. (Pubitemid 36254436)
19. Chen, J.; Wang, S.; Jia, X.; Bajimaya, S.; Tam, V. H.; Hu, M. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab. Dispos. 2005, 33 (12), 1777-1784. (Pubitemid 41697261)
20. Hu, M.; Chen, J.; Lin, H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J. Pharmacol. Exp. Ther. 2003, 307 (1), 314-321. (Pubitemid 37151923)
21. Jia, X.; Chen, J.; Lin, H.; Hu, M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J. Pharmacol. Exp. Ther. 2004, 310 (3), 1103-1113. (Pubitemid 39108932)
22. Wang, S. W.; Chen, J.; Jia, X.; Tam, V. H.; Hu, M. Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties. Drug Metab. Dispos. 2006, 34 (11), 1837-1848. (Pubitemid 44771711)
23. Wang, S. W.; Chen, Y.; Joseph, T.; Hu, M. Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. J. Altern. Complementary Med. 2008, 14 (3), 287-297.
24. Crespy, V.; Morand, C.; Manach, C.; Besson, C.; Demigne, C.; Remesy, C. Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am. J. Physiol. 1999, 277 (1), G120-G126. (Pubitemid 29352652)
25. Walle, U. K.; Galijatovic, A.; Walle, T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol. 1999, 58 (3), 431-438. (Pubitemid 29281542)
26. Andlauer, W.; Kolb, J.; Furst, P. Absorption and metabolism of genistin in the isolated rat small intestine. FEBS Lett. 2000, 475 (2), 127-130. (Pubitemid 30365064)
27. Andlauer, W.; Kolb, J.; Furst, P. Isoflavones from tofu are absorbed and metabolized in the isolated rat small intestine. J. Nutr. 2000, 130 (12), 3021-3027. (Pubitemid 32005333)
28. Totta, P.; Acconcia, F.; Leone, S.; Cardillo, I.; Marino, M. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life 2004, 56 (8), 491-499. (Pubitemid 39582784)
29. Brett, G. M.; Hollands, W.; Needs, P. W.; Teucher, B.; R Dainty, J.; Davis, B. D.; Brodbelt, J. S.; Kroon, P. A. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br. J. Nutr. 2008, 19, 1-12.
30. Kanaze, F. I.; Bounartzi, M. I.; Georgarakis, M.; Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur. J. Clin. Nutr. 2007, 61 (4), 472-477. (Pubitemid 46605217)
31. Hu, M.; Sinko, P. J.; deMeere, A. L.; Johnson, D. A.; Amidon, G. L. Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J. Theor. Biol. 1988, 131 (1), 107-114.
32. Hu, M.; Roland, K.; Ge, L.; Chen, J.; Li, Y.; Tyle, P.; Roy, S. Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model. J. Pharm. Sci. 1998, 87 (7), 886-890. (Pubitemid 28319421)
33. Houston, J. B.; Kenworthy, K. E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 2000, 28 (3), 246-254.
34. Hutzler, J. M.; Tracy, T. S. Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 2002, 30 (4), 355-362.
35. D'Argenio, D. Z.; Schumitzky, A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software; Biomedical Simulations Resource. University of Southern California: Los Angeles, 1997.
36. Yamaoka, K.; Nakagawa, T.; Uno, T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 1978, 6 (2), 165-175. (Pubitemid 8384279)
37. Akaike, H. Information theory and an extension of the maximum likelihood principle. In 2nd International Symposium on Information Theory; Petrov, B. N., Csaki, F., Eds.; Akademia Kiado: Budapest, 1973; pp 267-281.
38. Davis, B. D.; Needs, P. W.; Kroon, P. A.; Brodbelt, J. S. Identification of isomeric flavonoid glucuronides in urine and plasma by metal complexation and LC-ESI-MS/MS. J. Mass Spectrom. 2006, 41 (7), 911-920.
39. Silberberg, M.; Gil-Izquierdo, A.; Combaret, L.; Remesy, C.; Scalbert, A.; Morand, C. Flavanone metabolism in healthy and tumor-bearing rats. Biomed. Pharmacother. 2006, 60 (9), 529-535. (Pubitemid 44635084)
40. O'Leary, K. A.; Day, A. J.; Needs, P. W.; Mellon, F. A.; O'Brien, N. M.; Williamson, G. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (Mrp2) in flavonoid metabolism. Biochem. Pharmacol. 2003, 65 (3), 479-491. (Pubitemid 36084565)
41. Chen, J.; Lin, H.; Hu, M. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother. Pharmacol. 2005, 55 (2), 159-169.
42. Rost, D.; Mahner, S.; Sugiyama, Y.; Stremmel, W. Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am. J. Physiol. 2002, 282 (4), G720-G726. (Pubitemid 34651651)
43. Takano, M.; Yumoto, R.; Murakami, T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 2006, 109 (1-2), 137-161.
44. Zhang, S.; Wang, X.; Sagawa, K.; Morris, M. E. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab. Dispos. 2005, 33 (3), 341-348.